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FUNCTIONAL CHARACTERIZATION OF STK11 VUS
ABSTRACT
Lung carcinomas are the leading cause of cancer-related mortality in Vermont, and
approximately 30% of non-small cell lung carcinomas (NSCLC) have mutations in the
tumor suppressor gene Serine/Threonine Kinase 11 (STK11). Acting as a cellular energy
sensor, STK11 regulates cell growth, metabolism, and migration. In KRAS-driven
NSCLC, STK11 loss of function mutations correlate with more aggressive lung tumors,
metastasis, and poorer response to immunotherapy. STK11 functional status is therefore
clinically useful to predict disease prognosis and guide treatment. Mutations in STK11 are
functionally characterized as (likely) pathogenic, (likely) benign or a variant of unknown
significance (VUS). Clinicians at UVMMC utilized next generation sequencing of patient
lung adenocarcinomas to identify genetic mutations in genes known to impact prognosis
or treatment, including STK11. Twenty-eight missense alterations in the coding region of
the STK11 gene were identified as un- and under-characterized variants. This research
presents data that characterizes the function of the twenty-eight STK11 missense VUS
using a tissue culture reconstitution model and p53-dependent luciferase reporter assay.
When our data was compared to twenty-two different in silico predictive algorithms, there
were inconsistent functional predictions for the majority of the variants, which highlights
the importance of creating a reliable functional assay that can rapidly asses STK11
missense variants. Additionally, we developed an in vitro radioactive kinase assay to
analyze the biochemical kinetics of WT-STK11 and the twenty-eight variants. Our results
provide information that can guide clinical utilization of immunotherapy and help predict
prognosis for patients with NSCLC.
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INTRODUCTION
STK11 Function
Serine/Threonine Kinase 11 (STK11), formerly called Liver Kinase B1 (LKB1), is a
tumor suppressor protein that acts as a cellular energy sensor and regulates cell
metabolism, proliferation, polarity, and migration. It can exist in the nucleus where it
regulate transcription or in the cytoplasm where it is able to carry out its kinase function1.
The STK11 gene is composed of nine coding exons and the STK11 protein has three
domains: the N-terminus regulatory domain, the catalytic kinase domain spanning from
amino acids 49-309 (Figure 1), and the C-terminus regulatory domain2,3.

The N-terminus regulatory
domain contains a nuclear
localization sequence and
the

C-terminus

domain

contains a prenylation motif
that is important for proteinprotein

and

protein-

Figure 1. Location of twenty-eight clinically identified STK11
missense variants. Protein map of STK11 that details the locations
of somatic missense VUS identified from UVMMC. The gene is
divided into nine exons. The N-terminus regulatory domain (amino
acids 1-48) contains a nuclear localization sequence. The catalytic
kinase domain of STK11 encompasses amino acids 49-309 and is
indicated by the teal bar. It is important for ATP and substrate binding.
All the variants we identified to have loss of STK11 function fell withing
the kinase domain. The C-terminus domain (amino acids 309-433)
contains a prenylation motif that is important for protein-protein and
protein-membrane interactions. The majority of the variants were
missense mutations, however, there was one variant that contained a
deletion (K84del) and another that contained a nonsense mutation
(Y60*). The variant Q156_S169_del resulted from a new splice site
that caused the mRNA to be processed differently, resulting in a 14
amino acid deletion.

membrane interactions3,4. STK11 exists as a heterotrimer; its kinase activity is enhanced
by interactions with its protein binding partners STRADa and MO25. STRADa is referred
to as pseudokinase because it lacks several amino acid residues that are necessary for
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typical intrinsic catalytic activity of protein kinases.5 Even though pseudokinases do not
have catalytic activity, they serve important roles in substrate binding and enhancing the
activity of other kinases. Unlike many kinases, STK11 is not activated upon
phosphorylation by an upstream kinase; rather, the pseudokinase domain of STRADa
binds directly to the STK11 kinase domain, enhancing its activity over 100-fold6. MO25
interacts with both STK11 and STRADa and acts as a scaffolding protein to stabilize the
interaction between STK11 and STRADa.7 Together, STRADa and MO25 help stabilize
STK11 in an active complex and localize it to the cell cytoplasm where it can fulfill its role
as a tumor suppressor and cause cell cycle arrest.
STK11 has been found to be the major upstream kinase that regulates the AMPactivated protein kinase (AMPK) cascade8. When metabolic homeostasis is disrupted and
there is an elevated cytoplasmic AMP/ATP ratio, the active STK11 complex directly
phosphorylates AMPK to stimulate catabolic reactions further downstream9. In normal
energy conditions, STK11/AMPK serves to negatively regulate pathways such as mTOR
and MAPK that can promote tumorigenesis if left unchecked9. Therefore, loss of function
mutations in STK11 results in the inability to regulate downstream cancer-related
signaling pathways.
STK11 can activate other proteins in addition to AMPK. One notable downstream
substrate of STK11 is the tumor suppressor protein TP53 (p53), also known as the
guardian of the genome. P53 transcriptionally regulates genes related to cell cycle arrest,
DNA repair, and apoptosis2. STK11 has been found to physically interact with p53 and
activate it directly or indirectly through AMPK. STK11 has been reported to be an
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upstream signaling molecule that regulates p53-dependent apoptosis10. It also has been
coupled to p53-dependent anoikis and suppression of metastasis with salt-inducible
kinase 1 (SIK1)11.

STK11 and Lung Cancer
Lung cancer is the leading cause of cancer-related deaths according to the World
Health Organization with non-small cell lung carcinoma (NSCLC) being the most common
form. STK11 is one of the most commonly mutated genes in NSCLC, with approximately
30% of all cases presenting with STK11 mutations12. In lung cancer, STK11 mutations
are predominantly somatic as opposed to germline. STK11 loss of function mutations are
associated with increased tumor aggressiveness, distant metastasis, resistance to
immune modulating therapy, and shorter median overall survival13. NSCLC patients who
do not respond to combination therapy are referred to immunotherapy, currently the
leading line of therapy for advanced stage lung cancers. Immunotherapy uses
monoclonal antibodies to block the PD-1/PD-L1 pathway that these tumors use to evade
the immune system14. However, there is increasing evidence that indicates loss of
function mutations in STK11 drive resistance to PD-1 immunotherapy15,16. Furthermore,
NSCLC patients harboring STK11 mutations were shown to have shorter progressivefree survival15. The therapy itself is also very expensive, therefore, understanding the
impact of genetic alterations on the function of the STK11 protein provides important
clinical information that can help guide patient care.
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Next Generation Sequencing and Variants of Unknown Significance
The use of next generation sequencing (NGS) has greatly expanded the
understanding of genetic differences between normal and cancerous cells, especially for
solid tumors. In clinical oncology, NGS is used as a tool to evaluate patient tumor profiles
to guide targeted therapy and supply prognostic information. NGS has expanded the
scope of genetic alteration data that is available to clinicians in open resource databases;
however, this abundance of information can come with its own clinical challenges.
Typically, genetic variations are classified as either benign, likely benign, likely pathogenic
or pathogenic. Variant classifications are made based on various types of data, some of
which include clinical population studies, in vitro cell culture drug screens, and in silico
bioinformatics analyses. Often times, however, there is insufficient evidence to designate
a functional impact. Under these circumstances, the genetic variations are given the
name “variants of unknown significance” (VUS). This often occurs for rare or novel VUS
when there is little published information regarding their functional status. VUS with
mutations in the coding regions of genes have been the primary target of cancer-related
research because they can be more easily analyzed based on the cellular impacts of their
associated amino acid changes17. Coding region VUS include synonymous, nonsense
and missense mutations as well as deletions, insertions, and translocations. VUS can
also be found in non-coding regions of genes. Determining their impact is more
challenging because of difficulties in ascribing their function as well as the sheer size of
the non-coding region of the human genome and the number of mutations identified within
it17. Most non-coding VUS that are being investigated at this time are splice site variants,
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although more information about alterations in non-coding regulatory regions is
emerging17. The uncertainty of VUS function poses difficulties for clinicians
recommending treatment and follow-up for patients. It can also cause unwarranted stress
and anxiety for patients who undergo genetic testing and receive inconclusive results18.
Therefore, it is clear that being able to functionally characterize variants of unknown
significance in patient tumor samples is pertinent for guiding clinicians in planning patient
treatment and improving the quality of patient care through precision medicine.

Project Goals and Objectives
The overall goal of this project was to investigate the functional status of twentyeight missense STK11 VUS that molecular pathologists at the University of Vermont
Medical Center using NGS (Table 1). To do this we carried out this work through the
following aims:

AIM 1. Characterize the ability of STK11-WT or STK11

VUS to activate a

downstream substrate (p53) in a cell culture model system. A study conducted by
Jiang et al. took advantage of STK11-dependent p53 activation in order to investigate the
effects of hereditary STK11 gene mutations found in Peutz-Jeghers syndrome (PJS)2, a
cancer predisposition syndrome associated with the development of non-cancerous
hamartomatous polyps and increased risk of GI, pancreatic, cervical, ovarian and breast
carcinomas. In this study, the effect of STK11 germline mutations on the transcriptional
activity of p53 was examined using a p53-induced dual luciferase reporter assay. We

7

FUNCTIONAL CHARACTERIZATION OF STK11 VUS
employed a similar assay to assess the impact of un- and under-characterized STK11
variants. To do this, the STK11 variants were reconstituted into mammalian expression
plasmids using site-directed mutagenesis. A tissue culture reconstitution system using
A549 lung adenocarcinoma cells that do not express STK11 was employed. STK11
functional activity was assessed for each variant by measuring STK11-mediated
transcriptional activation of p53 using a p53-induced dual luciferase reporter assay2. The
results from this assay were then compared to twenty-two in silico prediction algorithms
that evaluate the likely functional impact on STK11 based on the location of the missense
mutation.

AIM 2. Develop an in vitro kinase assay allowing for the determination of STK11 WT
versus STK11 VUS phosphorylation kinetics. To gain an understanding of the
biochemical properties of STK11 missense VUS, including catalytic efficiency, KM, and
ATP sensitivity, a radioactive kinetic kinase assay was developed. To do this, we purified
flag-tagged STK11 from HEK-293 cells and then performed radioactive in vitro kinase
assays with a direct substrate of STK11, NUAK 2 peptide (LKBtide)19.

The results from these experiments provide information as to the function of
twenty-eight missense STK11 VUS, which will add to the knowledge clinicians use when
making medical decisions for patients with lung adenocarcinoma.
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MATERIALS AND METHODS
Materials
Dulbecco’s modified eagle’s medium (DMEM) was purchased from Thermo
Scientific (Waltham, MA, USA), fetal bovine serum (FBS) was obtained from R&D
Systems (Minneapolis, MN, USA). Wild-type (WT; Addgene #8590) and kinase dead
(K78I; Addgene #8591) STK11 plasmids, the STRADa plasmid (Addgene #14889), and
the p53-driven firefly luciferase (PG13-luc) and constitutive Renilla luciferase (pRL-SV40)
plasmids were obtained from Addgene (Cambridge, MA, USA). Polyethylenimine (PEI
25K™) transfection grade was obtained from Polysciences (Warrington, PA, USA). Pierce
(TM) BCA Protein Assay Kit (#23227) was obtained from ThermoFisher (Waltham, MA,
USA). Anti-DYKDDDDK Magnetic Agarose (A36797) and Dynabeads™ Protein
A (10001D) were purchased from Thermo Scientific (Waltham, MA, USA). 3X FLAGÒ
Peptide (F4799), ATP (A2383), and LKBtide peptide (12-540) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Recombinant AMPK (ab202156) was purchased
from Abcam (Cambridge, MA, USA). Coomassie Brilliant Blue (02190682-CF) was
obtained from MP Biomedicals (Santa Ana, CA, USA). Radioactive ATP [γ-32P]6000Ci/mmol (BLU502Z250UC) was purchased from PerkinElmer (Waltham, MA, USA).
Whatman p81 filter paper (3698-321) was purchased from GE Healthcare Life Sciences
(Piscataway, NJ, USA). Antibodies directed against LKB1 (E-9; #sc-374334), p53 (D0-1;
#sc-126), and Actin (C-2; #sc-8432) were obtained from Santa Cruz Biotechnology
(Dallas, TX, USA) and Phospho-AMPKa (#2535) was obtained from Cell Signaling
Technology (Danvers, MA, USA). Secondary antibodies, a-mouse-HRP and a-rabbit-
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HRP, were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA,
USA). Secondary antibody a-goat-HRP (#sc-2020) was obtained from Santa Cruz
Biotechnology (Dallas, TX, USA). All other reagents were purchased from Fisher
Scientific (Waltham, MA, USA) unless otherwise noted.

Variant Identification
STK11 missense variants were identified by searching the Genetic and Molecular
Pathology clinical sequencing database at the University of Vermont Medical Center. In
total, twenty-eight STK11 missense variants within the coding region of the gene (Table
1) were selected for further functional evaluation. The locations of these variants within
the STK11 protein sequence are highlighted in Figure 1.

Site-Directed Mutagenesis
Variants of unknown significance were generated in a mammalian expression
vector using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs, Ipswich, MA)
following manufacturer’s protocol. Briefly, DNA primers containing the variant of interest
were designed using NEBcloner.com. PCR was utilized to incorporate the change into a
vector encoding WT-STK11. The PCR product was ligated and transformed into DH5a.
Variant STK11 alleles were confirmed via Sanger sequencing performed at the Vermont
Integrative Genomics Resource at the University of Vermont. Primers used to generate
each variant are listed in Table 2.
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Tissue Culture and Transfection
A549 cells (ATCC #CCL-185) that are known to harbor a pathogenic nonsense
mutation in the STK11 gene resulting in a loss of protein were maintained in DMEM
containing 10% FBS and 2mM L-glutamine in a humidified environment at 37 ºC and 5%
CO2. Cells were seeded into a 12 well plate 18-20 hours before transfection so they would
be 70-80% confluent at time of transfection. 500ng STK11/eGFP, 500ng PG13-luc, and
250ng pRL-SV40 plasmid DNA (Addgene, Cambridge, MA) were added to cells with
Lipofectamine 3000 (Invitrogen, Carlsbad, CA) following manufacturer’s protocol.
HEK-293 cells (ATCC® CRL-1573™) were maintained in DMEM containing 10%
FBS and 2mM L-glutamine in a humidified environment at 37ºC and 5% CO2. Cells were
seeded into a 10 cm plate 24 hours before transfection so they would be ~80% confluent
at the time of transfection. To transfect the cells, 5.79 µg of WT-STK11 and STRAD-a
was used in combination with PEI (Polysciences, Warrington, PA). The PEI to DNA ratio
was 5 mL of PEI for every 1 µg of DNA. DMEM was added to this transfection mixture to
raise the volume to 450 mL. The transfection mixture was incubated for 25 minutes and
added dropwise to the plate.

Luciferase Assay
Eighteen hours post transfection, A549 cells were washed once in 1X PBS and
harvested using Passive Lysis Buffer provided with the Luciferase Assay Kit (Promega,
Madison, WI). The luciferase assay was performed following manufacturer’s protocol and
read using a SpectraMax M4 Plate Reader (Molecular Devices, San Jose, CA). Firefly
luciferase activity was normalized to the constitutively expressed Renilla luciferase in
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order to rule out differences in luminescence due to varying transfection efficiencies. The
fold-change of STK11-dependent p53 luciferase activity was obtained by normalizing
each condition’s luciferase activity to the GFP empty vector control. The luciferase signal
for each variant was analyzed with respect to WT-STK11 signal by an unpaired student
t-test.

In Silico Predictions
Predictions for each of the twenty-two in silico algorithms were attained using
VarSome: The Human Genomic Variant Search Engine20.

STK11 Immunoprecipitation & Elution
Twenty-four hours post-transfection, HEK-293 cells were harvested using a
binding buffer (25mM TRIS-HCl pH 7.4, 150mM NaCl, 1mM EDTA, 1% NP-40, 5%
glycerol) plus a protease inhibitor cocktail. Protein was quantified using a BCA Protein
Assay Kit following manufacturer’s protocol (ThermoFisher, Waltham, MA). Prior to
immunoprecipitation, 5 mg of cell lysate was pre-cleared for 30 minutes with
Dynabeads™ Protein A (Thermo Scientific, Waltham, MA) and the Anti-DYKDDDDK
Magnetic Agarose (Thermo Scientific, Waltham, MA) was blocked for 30 minutes with
binding buffer plus 1% BSA (BP1600-100 Fisher Scientific, Waltham, MA). Next, the
precleared cell lysate was subjected to immunoprecipitation using Anti-DYKDDDDK
Magnetic Agarose (Thermo Scientific, Waltham, MA) following manufacturer’s protocol.
The agarose beads bind to the FLAG-tagged N-terminus region of STK11 that was
overexpressed in the HEK-293 cells. STK11 was then eluted off the Anti-DYKDDDDK
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Magnetic Agarose using 3X FLAGÒ Peptide (Sigma-Aldrich, St. Louis, MO) following
manufacturer’s protocol. WT-STK11 eluate was subjected to SDS-PAGE electrophoresis.
Western blot analysis for STK11 and Coomassie staining were performed to determine
expression and purification quality. Standards of purified bovine serum albumin were
used to determine relative concentration of the STK11 protein. The gel was stained with
Coomassie Brilliant Blue (50% methanol, 40% acetic acid, 0.25% Coomassie Blue dye
(MP Biomedicals, Santa Ana, CA)) for one hour and allowed to de-stain in a solution that
was 40% methanol and 10% acetic acid for 24 hours. The gel was then imaged with a
PXi4 EX imaging system (Syngene, Frederick, MD, USA).

Cold Kinase Assay
The purified STK11 protein obtained from the FLAG peptide elution was subjected
to a cold kinase assay to determine whether the purification protocol rendered the STK11
kinase active. STK11 eluate was incubated in a kinase buffer (50 mM TRIS-HCl pH 7.5,
10 mM MgCl2, 1 mM DTT, 50 mM beta glycerol phosphate) plus or minus 100 µM ATP
(Sigma-Aldrich, St. Louis, MO) to monitor for STK11 autophosphorylation. Purified STK11
was also incubated in the same kinase buffer (plus and minus ATP) with the addition of
100 ng recombinant AMPK (abcam, Cambridge, MA). The recombinant AMPK was
comprised of partial AMPK a1 subunit that contained the STK11 phosphorylation site at
residue Thr-172. The reactions proceeded at 37ºC for 90 minutes in a shaker at 1400
rpm. The samples were then subjected to SDS polyacrylamide electrophoresis (PAGE)
and western blot analysis to monitor for phosphorylation on STK11 and AMPK.
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Western Blotting
Protein extracts were subjected to SDS-PAGE electrophoresis and transferred to
a nitrocellulose membrane using a Trans-Blot Turbo Transfer System (Bio-Rad
Laboratories, Hercules, CA, USA). Membranes were blocked for 1 hour at room
temperature in 1% BSA in 1X Tris-buffered saline + 0.1% Tween-20 (TBST). Primary
antibodies were diluted 1:1000 in 1% BSA in TBST and incubated overnight at 4 ºC.
Membranes were washed 3 times in TBST for 10 minutes each prior to incubation with
secondary antibody. Secondary antibodies were diluted 1:5,000 (a-mouse-HRP; a-goatHRP) or 1:10,000 (a-rabbit-HRP) in TBST and rocked with the membrane for 1 hour at
room

temperature.

Membranes

were

subject

to

SuperSignal

West

Pico

Chemiluminescent Substrate (Thermo Scientific, Waltham, MA, USA) following three
washes in TBST and imaged with a PXi4 EX imaging system (Syngene, Frederick, MD,
USA).

Radioactive Kinase Assay
Purified WT-STK11 kinase phosphotransferase activity towards the LKBtide
peptide was measured in a 50 μL assay volume consisting of 50 mM Tris/HCl pH 7.5, 0.1
mM EGTA, 0.1% (by vol) 2-mercaptoethanol, 10 mM DTT, 10 mM magnesium acetate, 1
mg/mL BSA, 0.1 mM [γ-32P] ATP (PerkinElmer, Waltham, MA) with a radioactivity of 300400 cpm/pmol) and LKBtide peptide (Sigma-Aldrich, St. Louis, MO) ranging from 0.488250 μM19. Each reaction was carried out in a 37ºC water bath for 30 minutes. The reaction
was quenched by adding 40 μL of the reaction volume onto p81 filter papers (GE
Healthcare, Piscataway, NJ). The filter papers were washed in 75 mM phosphoric acid

14

FUNCTIONAL CHARACTERIZATION OF STK11 VUS
and the radioactivity was measured using scintillation counting as previously described
for cGMP-kinase21.

RESULTS
Luciferase Assay
Discovering a reliable way to rapidly determine the function of missense variants
in various genes provides a major barrier to advancing the use of personalized genomic
medicine. This is in part because NGS and other techniques provide large amounts of
data that require time and money to properly sort through. To help alleviate this burden
and attempt to characterize missense variants, many in silico algorithms have been
created to predict the probability that a given mutation may alter a protein’s function22.
These algorithms take the missense mutation for a particular gene and compare it to the
wild-type protein sequence and structure. They predict pathogenicity based on an
analysis of how the amino acid change will impact the protein’s three dimensional
structure, which therefore, coincides with its function. Additionally, if the amino acid
change impacts binding to a cofactor, ATP, substrate, or binding partner, then the variant
could be predicted to be likely pathogenic. When using these various algorithms to predict
the function of STK11 missense mutations, inconsistent results are found (Figure 3B).
This uncertainty hinders a clinician’s proper interpretation of a patient’s tumor mutation in
STK11, which detracts from their ability to recommend the best course of treatment.
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In order to properly characterize the functional impact of clinically identified STK11
somatic coding region missense VUS (Table 1), we used a p53 luciferase reporter assay
previously described to evaluate the pathogenicity of germline STK11 gene mutations in
Peutz-Jeghers Syndrome2. This in vitro assay relies upon the ability of STK11 to activate
the transcriptional activity of p532,23. We reconstituted twenty-eight STK11 missense
variants identified in NSCLC tumors (Table 1) using site-directed mutagenesis of the WT
STK11 cDNA. The primers that were used to introduce the desired variant mutations into
the STK11-WT mammalian expression plasmid are detailed in Table 2A. A known kinasedead mutant (K78I)24 was used as a negative control for STK11 function in each
experiment. We then transiently transfected STK11-null A549 lung adenocarcinoma cells
(these cells contain a pathogenic nonsense mutation that results in a loss of the STK11
protein) with either STK11 WT, K78I or one of the twenty-eight VUS along with a p53driven firefly luciferase reporter and a constitutively expressed Renilla luciferase reporter.
STK11-dependent p53 luciferase activity
was then measured for the variants. Firefly
luciferase activity was normalized to the
Figure 2. Western blot analysis exhibiting
STK11 missense variant expression in A549
cell extracts used in the luciferase assays.
A549 cells were transiently transfected with WT or
VUS STK11 plasmids. The cells were harvested
and exposed to SDS-PAGE and western blot
analysis using the indicated antibodies. AntiSTK11 antibody analysis shows that STK11 was
expressed across all cells extracts we used in the
luciferase assays, save for Y60* as this nonsense
mutation results in an incomplete STK11 protein.
Here, we also show that p53 expression is not
impacted by the presence of STK11 as it is
expressed at steady levels in all extracts. Actin is
used as a loading control.
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constitutively expressed Renilla luciferase in order to rule out differences in luminescence
due to varying transfection efficiencies in each variant. The uniform expression of the fulllength STK11 protein in each lysate was confirmed using western blot analysis (Figure
2). Additionally, p53 expression was equivalent across all conditions (Figure 2).
There was roughly a three-fold increase in luciferase activity when cells were
reconstituted with WT-SKT11 compared to empty vector GFP (Figure 3A). The function
of each variant was compared to the WT-STK11 luciferase signal, causing the variants to

A

B

Figure 3. Functional impact of twenty-eight clinically identified STK11 missense variants. STK11-null
A549 lung adenocarcinoma cells were transiently transfected with STK11 WT, K78I or the twenty-eight VUS
along with a p53-driven firefly luciferase reporter and a constitutively expressed Renilla luciferase reporter. Cell
lysates were subjected to a STK11-dependent p53 luciferase reporter assay. (A) Graphical representation of
STK11-dependent p53 luciferase activity normalized to an empty vector GFP control using data obtained from
a dual luciferase reporter assay. Asterisks represent significance when VUS were analyzed in comparison to
WT-STK11 signal using an unpaired student t-test (n≥ 5 for all samples, p<0.05). STK11 VUS fall into two
functional categories: significant loss of STK11-dependent p53 luciferase activity compared to WT (red) and no
significant change in luciferase activity compared to WT (green). (B) Luciferase assay characterization of
STK11 missense VUS pathogenicity using an in vitro functional assay compared to that of 22 pathogenicity
predication algorithms that categorize functionality based on amino acid changes. The “red” indicates likely
pathogenic and the “green” indicates likely benign. The “gray” boxes in ClinVar Database represent uncertain
significance and the “white” indicates that no information is available or there were conflicting reports. Only two
VUS agree across all algorithms and our functional assay (G163R & D194Y).
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fall into two functional categories: likely benign (green bars) or likely pathogenic (red
bars). These functional results were then compared to twenty-two in silico predictive
algorithms, as previously mentioned. Since these algorithms can only be used to predict
missense variant pathogenicity and not deletions or nonsense mutations, the variants
Y60*, K84 del, and Q156_S169_del were not included in this comparison. As seen in
Figure 3B, there were some discrepancies between our functional assay data and the in
silico tools used to predict STK11 variant pathogenicity. Only six out of the twenty-eight
variants we assessed had uniform agreement across all twenty-two algorithms and our
functional assay (G56W,G163R, P179R, D194Y, G242V, and A397S). The function of
many variants in our luciferase assay agreed with the majority of the prediction algorithms
(Q112E, F148S, G155R, S193Y, S216F, P221R, A241P, G251C, P280A, R297M,
W308R, K311N, F354L, R409W, A417A). The algorithms were roughly split when it came
to the function of the variants R104G, H202R, and R211Q. Lastly, two variants (S31F and
P275L) were predicted to behave opposite of what was found in the luciferase functional
assay. Therefore, these results show that these in silico tools are not consistent/reliable
when compared to functional assays and should be used with caution with regard to
informing patient treatment.

Analysis of STK11 Kinetic Activity
We next wished to examine whether there was an impact of the STK11 VUS on
the kinetic properties of the enzyme. To begin this work, we expressed and purified
STK11 protein from HEK-293 cells and then we developed and optimized a radioactive
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kinase assay using the purified STK11 protein. To purify the active STK11 protein,
plasmids encoding FLAG-tagged WT-STK11 and 6xHis-tagged STRADa were cotransfected into HEK-293 cells that endogenously produce low levels of MO25. STRADa
was used because it is known to enhance STK11 catalytic activity and better represents
the native state of the enzyme as it is found in the cell6. Additionally, in reviewing the
literature, STRADa is often co-expressed with STK11 in kinase assays19,25. Multiple
optimizations were necessary to purify STK11 from HEK-293 cells and ensure that the
protein yield was high enough to perform radioactive kinase assays (Table 3).
STK11 Purification Optimizations
Harvest cells 48 hours post-transfection

X

Harvest cells 24 hours post-transfection

✓

Elute STK11 off anti-FLAG beads using enterokinase enzyme. This protease cleaves
the amino acids linking the FLAG tag to the N-terminus of the STK11 protein
Elute STK11 off anti-FLAG beads with FLAG peptide via competitive binding

✓

Use 150 ng/μL of FLAG peptide to elute STK11 off anti-FLAG beads

X

Use 1.5 μg/μL of FLAG peptide to elute STK11 off anti-FLAG beads

✓

To elute STK11 off the anti-FLAG beads, incubate the complex with FLAG peptide for
30 minutes
To elute STK11 off the anti-FLAG beads, incubate the complex with FLAG peptide for
45 minutes

X

X
✓

Table 3. Optimizations of SKT11 purification. The experimental protocol that was used to
purify STK11 was optimized after troubleshooting various methods. The different techniques that
were attempted are listed in the table. Those that contain a check mark represent the techniques
that were used to purify STK11 as previously described in Methods.

To obtain a high protein yield, the optimal time to harvest the cells after transfection was
found to be twenty-four hours as opposed to forty-eight. After harvesting the cells,
STK11/STRADa was pulled down using anti-FLAG beads that recognized the FLAG tag
at the N-terminus of the STK11 protein. Removing the protein complex from the beads
proved challenging. Attempts were made to cleave STK11 off the beads using a protease
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called enterokinase. Enterokinase cleaves the bond between the amino acid at the Nterminus of STK11 and the FLAG tag. This strategy failed to yield the desired results, so
we decided to change our approach and elute STK11/STRADa with FLAG peptide that
would out compete STK11 for bind ing on the anti-FLAG beads. This method proved
successful. Additional optimizations were necessary to deduce the ideal FLAG peptide
concentration and incubation time to yield the greatest amount of purified
STK11/STRADa (Table 3). After eluting the STK11/STRADa protein complex off the antiFLAG beads, the eluate was subjected to SDS-PAGE and Coomassie staining in order
to roughly quantify protein yield and inspect protein purity. Figure 4A shows that STK11
and STRADa were successfully eluted off the beads with a yield of approximately 10
ng/μL. The protein was not completely pure, as other protein bands are still visible in the
Coomassie gel of the eluted protein sample (Figure 4A). The isolated STK11/STRADa
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Figure 4. Coomassie gel and western blot analysis of WT-STK11 isolated from HEK-293 cell extracts.
WT-STK11 protein was isolated from HEK-293 cells and its activity verified before subjecting the kinase to a
radioactive biochemical assay. (A) Coomassie gel showing WT-STK11 extract after it had been eluted from
anti-FLAG beads using FLAG peptide. Lane: (1) 100 ng BSA, (2) 250 ng BSA, (3) 500 ng BSA, (4) 1000 ng
BSA, (5) WT-STK11 eluate showing STK11 running at approximately 55 kDa and STRADa running at 47
kDa. (B) Western blot analysis of WT-STK11 expression throughout the protein purification process. Lane:
(1) Whole cell extract (2) Immunoprecipitation of STK11 on anti-FLAG beads (3) Immunoprecipitation
supernatant (4) Anti-FLAG beads subsequent to FLAG peptide elution (5) Purified STK11 eluted off antiFLAG beads using FLAG peptide (C) Purified STK11 was subjected to a cold kinase assay (plus/minus ATP)
for an hour and a half. Purified STK11 was also incubated with recombinant 100ng AMPK and subjected to
a cold kinase assay (plus/minus ATP) for an hour and a half. Samples were then analyzed by SDS-PAGE
and western blot analysis using the indicated antibodies. STK11 autophosphorylation is seen in the presence
of ATP. The electrophoretic mobility shift, indicated by the arrow in the figure, signifies STK11
autophosphorylation. Recombinant AMPK phosphorylation at site T172 is seen in the presence of ATP.
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complex nevertheless retained its kinase function throughout the purification process. It
was still able to undergo autophosphorylation, which is indicated by the electrophoretic
mobility shift seen in Figure 4C. Others in the Deming Lab have shown that this
electrophoretic shift is due to autophosphorylation because the shifted band collapses
when the protein is subsequently treated with lambda phosphatase. The purified STK11
retained its kinase function in that it could successfully phosphorylate recombinant AMPK,
a known direct substrate of STK11, on Thr-172 in a cold kinase assay (Figure 4C)9. We
were able to monitor this phosphorylation using a commercially available phosphoantibody that recognizes phosphorylation of AMPK at Thr-172.
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Figure 5. WT-STK11 activity evaluated using a radioactive kinase assay.
(A) WT-STK11 was purified from HEK-293 cells using immunoprecipitation with
anti-FLAG beads and FLAG peptide elution. Purified STK11 was subjected to
an in-vitro radioactive kinase assay as described in Methods. The radioactivity
of [γ-32P] ATP that was transferred to LKBtide substrate was measured using a
scintillation counter. The counts are plotted as a function of the log of the LKBtide
substrate concentration (µM). (B) Raw values obtained in the radioactive kinase
assay are displayed. They were used to construct the plot in 5A.

measured using varying LKBtide (a known direct substrate of STK11) concentrations,
ranging from 0.488 – 250 μM19. The amount of radioactivity incorporated onto the LKBtide
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peptide was plotted as a function of the log of LKBtide substrate concentration (Figure
5). We expect to see a sigmoidal curve which would allow us to perform Michaelis-Menten
kinetic analyses and obtain catalytic efficiency and a KM value for WT-STK11 and
LKBtide. The exponential nature of the plot in Figure 5 suggests higher peptide
concentrations are needed to evaluate the kinetics of this isolated WT-STK11/STRADa
complex.

DISCUSSION
STK11 is an important tumor suppressor protein that senses energy levels in the
cell to control growth, proliferation, and migration through pathways that involve AMPK
and p53 signaling9,11. STK11 gene mutations are commonly found in NSCLC tumors. For
this reason, STK11 functional status is a useful tool to provide insight for prognosis and
therapy for patients diagnosed with NSCLC. STK11 somatic missense variants whose
functional status has yet to be determined are problematic and therefore emphasize the
importance of accurately predicting their function to use personalized genomic medicine.
Our findings show that STK11 function can be evaluated using an in vitro luciferase
assay with p53 as a readout. Sixteen out of the twenty-eight STK11 somatic missense
variants were classified as STK11 loss of function based on reduced p53-dependent
transcription of the luciferase reporter, leaving twelve predicted to retain their ability to
activate p53 (Figure 3A). The discrepancies between our functional assay data and the
in silico tools used to predict STK11 variant pathogenicity highlight the limitations of these
predictive algorithms. For example, only six of the variants agreed across all the
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algorithms and aligned with the results in the functional luciferase assay (G56W,G163R,
P179R, D194Y, G242V, and A397S). Additionally, S31F and P275L were predicted by
the majority of the algorithms to be pathogenic, yet our results suggest the opposite. The
majority of these STK11 missense variants are also characterized with uncertain
significance, conflicting reports, or had no information available in ClinVar, a repository
for germline variants that reports STK11 germline variants in the context of PJS. These
findings underscore the need to be able to rapidly and accurately characterize STK11
functional status in missense mutations because the predictive algorithms are not always
reliable.
The luciferase assay data provides a baseline characterization of function for the
STK11 missense mutations; however, it only confirms STK11 kinase activity and does
not provide any information about other structure-function implications that may result
from these mutations. For instance, the amino acid Ser-31 in STK11 has been shown to
be phosphorylated in vivo26, yet the variant S31F retained its kinase function in our
luciferase assay even though it could no longer be phosphorylated. Phosphorylation at
this site could play a regulatory role in a protein’s function or facilitate more efficient
binding to substrates. Additionally, this assay only illuminates STK11 kinase function in
terms of p53, a downstream substrate of STK11 that is involved in a multitude of other
cellular pathways as well. STK11 is involved in complex signaling of other pathways in
addition to p53, such as AMPK for example. By only looking at STK11-dependent p53
activation of the VUS we are confined to a narrow view of the many pathways STK11
regulates, pathways that these variants could very well be affecting. The ability of STK11
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to activate p53 does not preclude the possibility that there is a defect in other downstream
signaling events. The luciferase assay is also limited in its ability to yield information
regarding the biochemical impact of these mutations on STK11 function, including the
effects that altered substrate binding/affinity and sensitivity to ATP could have on the
efficiency of the kinase. Another point of consideration is that missense alterations of
STK11 in the C-terminus domain have been shown to impact the regulatory function of
STK1127. A study performed by Forcet et al. confirms our findings in that missense
mutations in the STK11 C-terminal region neither alter kinase function nor interfere with
STK11-induced growth arrest (p53 pathway)27. However, they show that mutations in the
STK11 C-terminal region, F354L in particular, reduce the activation of AMPK and
downstream signaling by STK11, thereby disrupting STK11 ability to maintain polarity27.
Therefore, STK11 missense VUS in the C-terminal domain may impact tumor migration
and metastasis, making it all the more crucial to characterize these variants by looking at
their biochemical effects through a variety of STK11 signaling pathways.
The radioactive kinase assay will expand our understanding of the findings in the
luciferase assay by providing data on the biochemical properties of the variants. For
example, it can provide more information about the biochemical properties of the STK11
variants that fell within the STK11 kinase domain that were classified as likely benign in
the luciferase assay. Although they were shown to retain kinase function, the missense
mutations could impact substrate binding or sensitivity to ATP. In the same way, more
can be concluded about the variants that the luciferase assay predicted to be pathogenic,
yet still showed intermediate levels of STK11 function (G251C). With this in mind, the
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radioactive kinase assay will provide more information about STK11 efficiency, its ability
to bind to its substrates, and its sensitivity to ATP. The biochemical analysis will expand
our view of the impact of these mutations on STK11 function by looking beyond STK11’s
role in the p53 pathway and investigating how these STK11 VUS impact the AMPK
signaling axis as well.
To perform the radioactive kinase assay, WT-STK11/STRADa complex had to be
purified; however, the purified complex that was used in the radioactive kinase assay was
shown to be contaminated with other proteins (Figure 4A). This minimal contamination
did not impact STK11’s ability to autophosphorylate or phosphorylate a direct substrate
(AMPK) (Figure 4C), suggesting that our purification protocol yielded active enzyme.
However, the preliminary results of the radioactive kinase assay with WT-STK11
demonstrate that further optimizations are still needed. For instance, in order to obtain a
sigmoidal curve necessary for kinetic analysis, the LKBtide substrate concentrations need
to be increased (Figure 5). Higher concentrations of substrate are required to saturate
the enzyme so the reaction can reach its maximum velocity and allow for kinetic analysis.
Additionally, the protein purification will need to be scaled up to allow for accurate
quantification of the amount of enzyme used in each reaction. The STK11 expression
system and immunoprecipitation purification method we detailed here is not yielding
enough STK11 to accurately quantify the enzyme. Others have reported success with
using baculoviruses that express chaperone proteins and insect Sf9 cells to enhance
STK11 protein production28,29. Additionally, high level expression of the functional STK11MO25- STRADa complex has been found in bacteria using a tricistronic vector system
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followed by purification with sequential immobilized-metal affinity and heparin
chromatography25. By increasing the substrate concentration and increasing and
quantifying the amount of STK11 in the kinase reaction, we will be able to apply MichaelisMenten assumptions to STK11 activity and extrapolate the KM and catalytic efficiency of
the enzyme.
Once the radioactive kinase assay is optimized and we have collected data on the
kinetics of the STK11 missense variants using LKBtide, the next step will be to investigate
the variants’ sensitivity to ATP. We will do this by holding the LKBtide substrate at a high,
fixed concentration and incrementally increase the amount of ATP in each reaction.
Michaelis-Menten kinetics will be applied to extrapolate the KM of STK11 VUS with ATP.
Investigating the sensitivity of STK11 VUS to ATP is important because an essential role
of STK11 is to act as a cellular energy sensor and respond to fluctuations in the AMP/ATP
ratio of the cell9. Therefore, any variants that are less sensitive to ATP could have reduced
ability to regulate AMPK and its downstream tumor promoting pathways.
In conclusion, the accurate evaluation of STK11 function in NSCLC tumors is
crucial for informing clinical decisions on prognosis and the use of anti-PD1
immunotherapy for patients with NSCLC diagnoses. STK11 genetic alterations have been
identified in the literature as the primary genomic drivers of nivolumab immunotherapy
resistance in KRAS-driven lung adenocarcinoma15. It has been found that tumors with
STK11 loss of function mutations have reduced expression of the PD-1 ligand, PD-L1,
which is the target of immunotherapy for NSCLC, thereby contributing to resistence16.
The results from our study show that reliance on in silico predictive algorithms alone is
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not sufficient to accurately ascribe the functional activity of STK11 to various somatic
missense variants. With further research into understanding the molecular interactions
and biochemical impact of STK11 missense VUS on patient tumors, we hope to provide
more reliable data that clinicians can use to predict how patients will respond to
immunotherapy for NSCLC in order to decide which treatment course is best based on
their tumor’s genetic profile.
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TABLES
Table 1. STK11 variants of unknown significance. Next Generation Sequencing
results of patient lung adenocarcinoma provided by molecular pathologists at UVMMC.
This list highlights genomic locations of STK11 missense variants. The nomenclature
references human genome build GRCh37/hg19.
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Table 2. Site-directed mutagenesis primer sequences. Table showing primers used
in site-directed mutagenesis to construct VUS DNA plasmids. Primers were designed
using NEBcloner.com and the mutated base is represented by the lower case base in the
forward primer. The primers were subjected to PCR to incorporate the mutation into a
WT-STK11 vector template.
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Table 3. Optimizations of SKT11 purification. The experimental protocol that was used
to purify STK11 was optimized after troubleshooting various methods. The different
techniques that were attempted are listed in the table. Those that contain a check mark
represent the techniques that were used to purify STK11 as previously described in
Methods.
STK11 Purification Optimizations
Harvest cells 48 hours post-transfection
Harvest cells 24 hours post-transfection
Elute STK11 off anti-FLAG beads using enterokinase enzyme. This
protease cleaves the amino acids linking the FLAG tag to the N-terminus
of the STK11 protein
Elute STK11 off anti-FLAG beads with FLAG peptide via competitive
binding
Use 150 ng/μL of FLAG peptide to elute STK11 off anti-FLAG beads
Use 1.5 μg/μL of FLAG peptide to elute STK11 off anti-FLAG beads
To elute STK11 off the anti-FLAG beads, incubate the complex with FLAG
peptide for 30 minutes
To elute STK11 off the anti-FLAG beads, incubate the complex with FLAG
peptide for 45 minutes

X
✓
X
✓
X
✓
X
✓
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